Tanvex BioPharma, Inc. (TPE:6541)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
36.60
-1.20 (-3.17%)
Jul 30, 2026, 1:30 PM CST

Tanvex BioPharma Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-1,423-1,500-1,382-2,137-1,641-1,543
Depreciation & Amortization
311.51320.63287.56323.59280.01241.43
Other Amortization
46.2946.11.481.241.552.15
Loss (Gain) From Sale of Assets
40.5246.91-0.082.877.210.94
Asset Writedown & Restructuring Costs
-49.19-8.67--
Stock-Based Compensation
10.829.07-2.16326.6167.5552.95
Provision & Write-off of Bad Debts
-4.86.47----
Other Operating Activities
-0.52-3.1517.88-1.23--90.2
Change in Accounts Receivable
-52.75211.259.33-9.062.19-2.52
Change in Inventory
-141.26-157.92-109.5562.56-80.51-40.25
Change in Accounts Payable
46.4299.59-33.41-15.59-66.97
Change in Unearned Revenue
171.14-68.36-0.56-10.9328.07-
Change in Other Net Operating Assets
-30.24-65.0727.05-35.9816.8258.67
Operating Cash Flow
-1,026-1,005-1,151-1,435-1,334-1,387
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-835.37-668.26-105.91-71.02-93.5-29.82
Sale of Property, Plant & Equipment
11.9712.910.146.331.826.7
Sale (Purchase) of Intangibles
-2.48-1.94-4.86-0.32-2.58-0.52
Other Investing Activities
949.56959.11.38-18.57-3.09-1.04
Investing Cash Flow
-880.59301.8-109.25-83.57-97.35-24.68

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-30377.65---
Total Debt Issued
13530377.65---
Short-Term Debt Repaid
---377.65---
Long-Term Debt Repaid
--156.67-184.58-127.67-130.53-93.11
Total Debt Repaid
-174.91-156.67-562.23-127.67-130.53-93.11
Net Debt Issued (Repaid)
-39.91-126.67-184.58-127.67-130.53-93.11
Issuance of Common Stock
1,2551,2641,4401,2077.241,690
Other Financing Activities
1.720.22----
Financing Cash Flow
1,2171,1381,2551,080-123.291,597

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
54.9667.640.9833.91117.75-31.25
Net Cash Flow
-634.95501.75-3.79-405.48-1,437154.37

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1,861-1,674-1,257-1,506-1,427-1,417
Free Cash Flow Growth
------
Free Cash Flow Margin
-384.63%-417.41%-3623.36%-2452.94%-6370.97%-26208.75%
Free Cash Flow Per Share
-7.28-6.83-8.09-11.69-12.14-13.05
Levered Free Cash Flow
-1,431-1,111-792.54-713.06-844.23-819.13
Unlevered Free Cash Flow
-1,402-1,082-759.2-677.19-810.03-790.24

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
46.2847.2353.3457.3854.7245.81
Cash Income Tax Paid
0.50.831.020.880.020.02
Change in Working Capital
-6.6819.49-73.7339.99-49.03-51.08